• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)".

作者信息

Bonaca Marc P, Sabatine Marc S

机构信息

TIMI (Thrombolysis In Myocardial Infarction) Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, MA.

出版信息

Circulation. 2018 Jul 10;138(2):222-223. doi: 10.1161/CIRCULATIONAHA.118.034864.

DOI:10.1161/CIRCULATIONAHA.118.034864
PMID:29986970
Abstract
摘要

相似文献

1
Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)".博纳卡和萨巴蒂内对关于《依洛尤单抗降低低密度脂蛋白胆固醇与外周动脉疾病患者的结局：FOURIER试验（在高危受试者中进行PCSK9抑制的进一步心血管结局研究）》一文的信件的回应
Circulation. 2018 Jul 10;138(2):222-223. doi: 10.1161/CIRCULATIONAHA.118.034864.
2
Letter by Alkhalil Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)".阿尔哈利勒就文章《依洛尤单抗降低低密度脂蛋白胆固醇与外周动脉疾病患者的预后：FOURIER试验（在高危受试者中使用PCSK9抑制剂的进一步心血管结局研究）的见解》所写的信
Circulation. 2018 Jul 10;138(2):220-221. doi: 10.1161/CIRCULATIONAHA.117.033207.
3
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)".卡拉布罗等人就文章《依洛尤单抗降低低密度脂蛋白胆固醇与外周动脉疾病患者的预后：FOURIER试验（在高风险受试者中使用PCSK9抑制剂的进一步心血管结局研究）的见解》所写的信。
Circulation. 2018 Jul 10;138(2):218-219. doi: 10.1161/CIRCULATIONAHA.117.033137.
4
Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.循环原蛋白转化酶枯草溶菌素 9 水平与依洛尤单抗疗效的相关性。
JAMA Cardiol. 2017 May 1;2(5):556-560. doi: 10.1001/jamacardio.2016.5395.
5
PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.抑制前蛋白转化酶枯草溶菌素9以降低低密度脂蛋白及其他作用——对周围动脉疾病患者的影响
Vasa. 2018 Apr;47(3):165-176. doi: 10.1024/0301-1526/a000689. Epub 2018 Feb 7.
6
A safety evaluation of evolocumab.依洛尤单抗的安全性评估。
Expert Opin Drug Saf. 2018 Jan;17(1):99-106. doi: 10.1080/14740338.2018.1389892. Epub 2017 Oct 16.
7
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.PCSK9 抑制剂依洛尤单抗降低 LDL-胆固醇水平的临床疗效和安全性：FOURIER 试验的预先设定的次要分析。
Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28.
8
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.依洛尤单抗在接受他汀类药物治疗的高危患者中的临床疗效和安全性：一项随机临床试验中 LDL 胆固醇水平较低的患者和已经接受最大强度他汀类药物治疗的患者的二次分析。
JAMA Cardiol. 2017 Dec 1;2(12):1385-1391. doi: 10.1001/jamacardio.2017.3944.
9
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂：当前观点与未来展望。
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
10
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.依洛尤单抗抑制纯合子家族性高胆固醇血症（TESLA Part B）：一项随机、双盲、安慰剂对照试验。
Lancet. 2015 Jan 24;385(9965):341-50. doi: 10.1016/S0140-6736(14)61374-X. Epub 2014 Oct 1.

引用本文的文献

1
Low-dose atorvastatin calcium combined with evolocumab: effect on regulatory proteins, lipid profiles, and cardiac function in coronary heart disease patients.小剂量阿托伐他汀钙联合依洛尤单抗：对冠心病患者调节蛋白、血脂谱及心功能的影响
Am J Transl Res. 2024 Jun 15;16(6):2334-2345. doi: 10.62347/ZGKO3645. eCollection 2024.
2
Higher risk of future events, mortality and greater healthcare use among patients with increasingly recurrent atherosclerotic cardiovascular disease events in Taiwan: a retrospective cohort study.在台湾，随着动脉粥样硬化性心血管疾病事件反复发作的患者未来事件、死亡率和医疗保健使用的风险更高：一项回顾性队列研究。
BMJ Open. 2023 Jul 19;13(7):e064219. doi: 10.1136/bmjopen-2022-064219.